Raltegravir potassium is the potassium salt form of raltegravir, a synthetic antiretroviral agent classified as an integrase strand transfer inhibitor (INSTI). It is primarily used in the treatment of HIV-1 infection by blocking the HIV integrase enzyme, which prevents the virus from integrating its genetic material into the DNA of host cells, thereby inhibiting viral replication and reducing viral load.

As a specialty pharmaceutical intermediate, raltegravir potassium is employed in the manufacture of combination antiretroviral therapies (ART) to enhance efficacy and combat drug resistance. It is particularly valuable for developing regimens in cases of resistance to other antiretroviral classes. This compound is supplied as a high-purity active pharmaceutical ingredient (API) for research, development, and production in pharmaceutical applications.

Chemical specifications typically include a white to off-white solid appearance, conformity to infrared spectrum structure, and purity of 96.5-100%.